Feb 5 (Reuters) - Mirum Pharmaceuticals Inc MIRM.O:
MIRUM PHARMACEUTICALS ANNOUNCES HEALTH CANADA AUTHORIZATION OF LIVMARLI® FOR THE TREATMENT OF CHOLESTATIC PRURITUS IN PATIENTS WITH PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS (PFIC)
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.